Almirall enters deal with Simcere on candidate ready for clinic
For a price that could exceed USD 500m, Chinese Simcere has signed away the global rights outside China to a potential treatment for a number of autoimmune disease.
by albert rønning-andersson, translated by daniel pedersen
Spanish dermatology group Almirall has made an agreement with Chinese pharmaceutical firm Simcere regarding the rights to develop and commercialize drug candidate SIM0278 outside Greater China, including Hong Kong, Macau, and Taiwan, a press release announces.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Almirall starts human trials of skin treatment
For subscribers
